DNA vaccines for the treatment of prostate cancer

Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, WI, USA.
Expert Review of Vaccines (Impact Factor: 4.22). 07/2010; 9(7):731-45. DOI: 10.1586/erv.10.64
Source: PubMed

ABSTRACT Prostate cancer is a significant public health problem, and the most commonly diagnosed cancer in the USA. The long natural history of prostate cancer, the presence of a serum biomarker that can be used to detect very early recurrences, and the previous identification of multiple potential tissue-specific target antigens are all features that make this disease suitable for the development of anti-tumor vaccines. To date, many anti-tumor vaccines have entered clinical testing for patients with prostate cancer, and some have demonstrated clinical benefit. DNA vaccines represent one vaccine approach that has been evaluated in multiple preclinical models and clinical trials. The safety, specificity for the target antigen, ease of manufacturing and ease of incorporating other immune-modulating approaches make DNA vaccines particularly relevant for future development. This article focuses on DNA vaccines specifically in the context of prostate cancer treatment, focusing on antigens targeted in preclinical models, recent clinical trials and efforts to improve the potency of these vaccines.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Considerable progress has been made in prostate cancer immunotherapy over the last year, and two agents have completed phase III testing. This review will discuss the most promising immune-directed strategies in development for prostate cancer, outlining interventions that mitigate tumor-induced tolerance and highlighting several combination immunotherapy approaches. A pivotal phase III study using Sipuleucel-T, an autologous prostatic acid phosphatase (PAP)-loaded dendritic cell immunotherapy, in men with metastatic castration-resistant prostate cancer (CRPC) demonstrated a survival advantage over placebo. By contrast, two phase III studies of GVAX, an allogeneic tumor cell vaccine, in a similar patient population failed to show a survival benefit of GVAX or GVAX/docetaxel over standard docetaxel/prednisone. Other strategies currently in clinical development include the ProstVac poxviral vaccine, a PAP-encoding DNA vaccine, and immune checkpoint inhibitory approaches. Although Sipuleucel-T may receive FDA approval for patients with metastatic CRPC, challenges remain in identifying immunotherapy strategies that overcome immune tolerance, especially when disease burden is substantial. An emerging paradigm focuses on using immunotherapy together with checkpoint antagonists or in combination with conventional therapies in patients with early-stage disease. Such approaches are likely to yield optimal results, but must carefully be explored in well designed phase II studies before moving forward.
    Current opinion in urology 02/2010; 20(3):241-6. DOI:10.1097/MOU.0b013e3283381793 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer immunotherapy has developed into a field of intense study as aspects of the immune system involved in the eradication of cancer have become delineated. Listeria monocytogenes is a gram-positive, facultative intracellular bacterium which infects antigen presenting cells (APC), and is being used as a cancer vaccine to deliver tumor antigens directly to the APC. This results in the generation of a strong immune response towards the tumor associated antigen and direct targeting of the tumor by the immune system. Advances in this field have led to the development of a series of L. monocytogenes-based cancer vaccines, which are currently in clinical trials. A phase I study has shown these vaccines can be safely administered and well-tolerated in terminal stage cancer patients and an efficacy signal was observed in patients who did not respond to other therapies. Additional data on the efficacy of these vaccines is expected in the near-term.
    Human vaccines 05/2011; 7(5):497-505. DOI:10.4161/hv.7.5.15132 · 3.64 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unintentional subdural injection during neuraxial anesthesia/analgesia continues to be a challenge for anesthesiologists. This unusual complication is often poorly recognized, with the diagnosis made in retrospect, or not at all. The clinical presentation of these regional blocks can be heterogeneous, ranging from restricted, patchy, or unilateral sensory blockade all the way to extensive and even life-threatening motor and autonomic nervous system depression. Prompt diagnosis using clinical algorithms and radiographic imaging is crucial for the early discontinuation of the offending catheter. Supportive care is mandatory in cases involving severe depression of consciousness, motor function, and/or sympathetic tone.
    Anesthesiology Clinics 06/2011; 29(2):279-90. DOI:10.1016/j.anclin.2011.04.002
Show more